IsoRay, Inc., a provider of innovative solutions for the treatment and diagnosis of disease using medical isotopes that represent significant advancements over existing technology, today announced an agreement with Karlheinz Goehl-Medizintechnik Goehl for the distribution of the GliaSite radiation therapy system in certain European markets. The GliaSite radiation therapy system includes a balloon catheter which is a unique technology that allows doctors to treat more brain cancer patients than brachytherapy or internal radiation therapy.
“The GliaSite® system represents continued progress toward our goal of expanding the use of brachytherapy solutions to treat cancers throughout the entire body. This distribution agreement allows us to pursue the recapture of the $4-5 million in annual revenue previously generated by product sales when Hologic owned the device. It also represents an important development for brain cancer patients and their doctors in providing a crucial treatment option that delivers improved outcomes and quality of life,” said Dwight Babcock, CEO, IsoRay Inc in a press release on Thursday.
Advantages of the GliaSite system include the ability to target a specified high dose of a liquid radiation source in the areas most likely to contain the cancer after a brain tumor has been removed. It is also less likely to damage healthy brain tissue, helps to minimize the possibility of the tumor recurring and provides patients with a better quality of life as it limits the number of follow-up external radiation treatments.
“In 2002, our company was the first to have patients treated with GliaSite® outside the U.S. We had great success in providing a safe, adjuvant and remarkably life-extending therapy for glioma patients whilst keeping their quality-of-life-index in the highest possible range, which was our main goal,” said Karlheinz Goehl-Medizintechnik Goehl President Charly Goehl in the Thursday press release. “Previous customers are very excited to have GliaSite® available again.”
Regulatory approval is expected for the new liquid form of IsoRay’s Cesium-131, an advanced form of brachytherapy for the treatment of brain cancer, that would use the GliaSite radiation therapy system for delivery. Cesium-131 allows for the internal radiation treatment of many different cancers since it combines its high energy ability to reach just far enough to treat the cancer and its half-life speed in giving off therapeutic radiation.
For more information, please visit www.isoray.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
